AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7733122
Drug: Tolbutamide 250
RxNorm normalized name: tolbutamide 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolbutamide 250 to 1,000 mg
Trial: 1914055
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg nalbuphine after lidocaine anaesthesia
Trial: 1914055
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg nalbuphine after lidocaine anaesthesia
Trial: 1914055
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg nalbuphine after lidocaine anaesthesia
Trial: 1914055
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg nalbuphine after 2-chloroprocaine anaesthesia
Trial: 1914055
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg nalbuphine after 2-chloroprocaine anaesthesia
Trial: 1914055
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg nalbuphine after 2-chloroprocaine anaesthesia
Trial: 31283920
Drug: Low-dose CT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CT screening (LDCT) in patients with COPD
Trial: 25694056
Drug: Candesartan (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (16 mg to 32 mg per day) in addition to routine standard of care
Trial: 22074866
Drug: Immediate loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate loading (IML) implants
Trial: 22074866
Drug: Conventional loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional loading implants
Trial: 19444561
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration therapy (1000 ml of oral rehydration solution)
Trial: 19444561
Drug: Intravenous therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous therapy (1000 ml of intravenous electrolyte solution)
Trial: 15198290
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (Genotropin, 1 mg/m2/day)
Trial: 11438316
Drug: Testosterone lozenge
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone lozenge (1 mg)
Trial: 11438316
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel (1 mg)
Trial: 9692520
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg orally every 12 h for 10 days
Trial: 9593146
Drug: Loratadine 10
RxNorm normalized name: loratadine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine 10 mg orally every 24 h for 10 days
Trial: 9593146
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clarithromycin and loratadine
Trial: 9593146
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three regimens (clarithromycin, loratadine, combination)
Trial: 7874080
Drug: Thymomodulin 10
RxNorm normalized name: thymomodulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymomodulin 10 mg three times per week for 2 months
Trial: 2896957
Drug: Treatment combined
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment combined with fortnightly chemoprophylaxis with 'Maloprim' (pyrimethamine/dapsone)
Trial: 2896957
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of presumptive episodes of clinical malaria with chloroquine
Trial: 25572706
Drug: Baclofen 50
RxNorm normalized name: baclofen 50 mcg/mL INTRATHEC KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen 50 mg/day
Trial: 16679630
Drug: Intravenous L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous L-carnitine 20 mg/kg after every dialysis session for 8 weeks
Trial: 15090626
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 g of high oleic acid sunflower oil)
Trial: 15090626
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g of cis‐9,trans‐11 (c9t11) CLA
Trial: 15090626
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g of cis‐9,trans‐11 (c9t11) CLA
Trial: 15090626
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g of trans‐10,cis‐12 (t10c12) CLA
Trial: 15090626
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g of trans‐10,cis‐12 (t10c12) CLA
Trial: 10856731
Drug: Metoprolol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (mean final dosage 135 mg/day)
Trial: 9355892
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (200 mg TID)
Trial: 3890036
Drug: Mepivacaine hydrochloride
RxNorm normalized name: Mepivacaine Hydrochloride
DrugBank: Mepivacaine (DB00961)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mepivacaine hydrochloride (1% solution)
Trial: 20306937
Drug: Involvement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Involvement of hospital chaplains in spiritual care during treatment.
Trial: 28973430
Drug: Antecedent hypoglycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antecedent hypoglycemia (3 periods of 45 minutes at 2.8 mmol/L)
Trial: 28973430
Drug: Control (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (3 periods of 45 minutes at 6 mmol/L)
Trial: 25932792
Drug: Combo therapy
RxNorm normalized name: NexGard Combo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combo therapy (ERN + P-OM3)
Trial: 16861099
Drug: Sibutramine 10
RxNorm normalized name: sibutramine 10 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine 10 mg QD
Trial: 12963170
Drug: Oral-conjugated oestrogen
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral-conjugated oestrogen 0.625 mg daily (n=13)
Trial: 12963170
Drug: Transdermal oestrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal oestrogen patches 50 microg daily (n=10)
Trial: 10720589
Drug: Allopurinol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (300 mg for 1 month)
Trial: 3299567
Drug: Ambroxol retard
RxNorm normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol retard (75 mg)
Trial: 29065710
Drug: Yoghurt drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoghurt drink containing Lactobacillus strains (125 g, twice daily for 4 weeks)
Trial: 29065710
Drug: Placebo (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (125 g chemically acidified milk, twice daily for 4 weeks)
Trial: 23607963
Drug: Topical vitamin
RxNorm normalized name: vitamin A Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical vitamin E once daily
Trial: 23607963
Drug: Emollient once
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emollient once daily
Trial: 11041396
Drug: rBPI21 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rBPI21 (2 mg/kg over 30 min followed by 2 mg/kg over 24 h)
Trial: 11041396
Drug: Placebo (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.2 mg/mL human albumin solution)
Trial: 8769511
Drug: 0.12% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine gluconate (CHX) oral rinse
Trial: 27090649
Drug: Pressure-Controlled Ventilation
RxNorm normalized name: VENTILATOR FILTER,THERMOFLO #6000S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressure-Controlled Ventilation (PCV) targeting large V T (15 mL × kg(‐1))
Trial: 19717399
Drug: TNF inhibitors
RxNorm normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF inhibitors + methotrexate (MTX)
Trial: 15886247
Drug: Metformin 2550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 2550 mg/d
Trial: 8874243
Drug: Smoked cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoked cocaine base (38.5 +/- 2.3 mg)
Trial: 8874243
Drug: i.v. cocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. cocaine HCl (30.0 +/- 2.0 mg)
Trial: 8874243
Drug: Smoked placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoked placebo (2.3 +/- 0.9 mg cocaine base)
Trial: 8874243
Drug: i.v. saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. saline solution placebo
Trial: 1509861
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg ciprofloxacin b.i.d. for 5 days
Trial: 6714054
Drug: Cimetidine and
RxNorm normalized name: Cimetidine and sodium alginate only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine and antacid suspension
Trial: 30919249
Drug: Perindopril/Amlodipine SPC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril/Amlodipine SPC (3.5/2.5 mg to 14/10 mg)
Trial: 30919249
Drug: Irbesartan (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (150 mg to 300/25 mg)
Trial: 19937046
Drug: SCH486757 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCH486757 100 mg
Trial: 15825069
Drug: Ornidazole 1
RxNorm normalized name: ornidazole 167 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ornidazole 1 g/day
Trial: 12442930
Drug: Lidocaine 1%
RxNorm normalized name: LIDOCAINE 1% LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1% 30 mL (+epinephrine 5 microg mL(‐1))
Trial: 12442930
Drug: Lidocaine 2%
RxNorm normalized name: LIDOCAINE 2% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2% 15 mL (+epinephrine 5 microg mL(‐1))
Trial: 1850870
Drug: Breast-preserving therapy
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast-preserving therapy with interdisciplinary communication among therapists (surgeon, radiotherapist, oncologist) and pathologist.
Trial: 1850870
Drug: Breast-preserving therapy
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast-preserving therapy under unfavorable prerequisites for cosmetically satisfactory results.
Trial: 6345013
Drug: Mefloquine 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine 1000 mg
Trial: 6345013
Drug: Mefloquine 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine 750 mg
Trial: 6345013
Drug: Mefloquine 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine 500 mg
Trial: 30628088
Drug: Adjunctive azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjunctive azithromycin (500 mg for 3 days)
Trial: 30628088
Drug: Adjunctive amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunctive amoxicillin plus metronidazole (500 mg AMX plus 400 mg MTZ three times per day for 7 days)
Trial: 22969203
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (PAM): pantoprazole 20 mg bid, amoxicillin 1 g bid, moxifloxacin 400 mg bid for 10 days
Trial: 22969203
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy (PAMB): pantoprazole 20 mg bid, amoxicillin 1 g bid, moxifloxacin 400 mg bid, bismuth subcitrate 240 mg bid for 10 days
Trial: 18001671
Drug: Cognitive-behavioural treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural treatment for smoking cessation without nicotine replacement
Trial: 12577415
Drug: Chemotherapy (CT)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CT) plus Xiaoliu Pingyi Mixture (XLPYM)
Trial: 7984290
Drug: Zatosetron (13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zatosetron (13 mg or 0.19 mg/kg)
Trial: 2644533
Drug: Adjuvant combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant combination chemotherapy (cyclophosphamide, methotrexate, fluorouracil, leucovorin) administered on days 1 and 8, starting within 36 hours after mastectomy
Trial: 19938102
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) at a standard dose of 2g per kg body weight
Trial: 15170013
Drug: COL-1492 vaginal
RxNorm normalized name: Col-118
DrugBank: Col-118 (DB05778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COL-1492 vaginal gel containing 52.5 mg nonoxynol-9
Trial: 10052024
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 ml saline intravenous)
Trial: 3142396
Drug: Methyldopa (MD)
RxNorm normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methyldopa (MD) 500 mg/bid, optimal dosage up to 1500 mg/bid
Trial: 3142396
Drug: Labetalol (LAB)
DrugBank: Labetalol (DB00598)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Labetalol (LAB) 400 mg/bid, optimal dosage up to 1200 mg/bid
Trial: 3142396
Drug: Acebutolol (ACE)
DrugBank: Acebutolol (DB01193)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acebutolol (ACE) 400 mg/bid, optimal dosage up to 1200 mg/bid
Trial: 30088008
Drug: 36-month family-based,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 36-month family-based, community-centered program (n=304 pairs) consisting of 12 weekly skills-building sessions, followed by monthly coaching calls for 9 months, and a 24-month sustainability phase.
Trial: 27623957
Drug: mesalazine 1200
RxNorm normalized name: mesalamine 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mesalazine 1200 mg plus a probiotic blend (Lactobacillus salivarius, Lactobacillus acidophilus, Bifidobacterium bifidus strain BGN4)
Trial: 27623957
Drug: mesalazine 1200
RxNorm normalized name: mesalamine 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mesalazine 1200 mg
Trial: 10435394
Drug: Risperidone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (1 mg single oral dose)
Trial: 7004559
Drug: Intravenous fluorouracil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fluorouracil, cyclophosphamide, methotrexate, and vincristine given over five days followed by intravenous fluorouracil and mitomycin given over three or five days at six-week intervals thereafter
Trial: 26488269
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard CDC information factsheet on HPV vaccine)
Trial: 22526891
Drug: Intraseptal anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraseptal anesthesia (ISA) with 4% articaine + 1:100,000 epinephrine (16 mg + 4 μg, 24 mg + 6 μg, 32 mg + 8 μg)
Trial: 22526891
Drug: Periodontal ligament
RxNorm normalized name: human ligament preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal ligament anesthesia (PLA) with 4% articaine + 1:100,000 epinephrine (16 mg + 4 μg, 24 mg + 6 μg, 32 mg + 8 μg)
Trial: 21546066
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (specifics not provided)
Trial: 21546066
Drug: CA-125 PFS
RxNorm normalized name: Ca 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CA-125 PFS status at 4 months (PFS4) in combination treatment
Trial: 21546066
Drug: CA-125 response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: CA-125 response in combination treatment
Trial: 21546066
Drug: CA-125 PFS4
RxNorm normalized name: Ca 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CA-125 PFS4 in combination treatment
Trial: 17990464
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard therapy without QYD and GS)
Trial: 9803988
Drug: Zabicipril (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zabicipril (0.5 mg)
Trial: 9803988
Drug: Zabicipril (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zabicipril (2.5 mg)
Trial: 389121
Drug: Pharmacologically inactive
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologically inactive dose (1 mg)
Trial: 25087311
Drug: Pentavac administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentavac administered second (Group A)
Trial: 25087311
Drug: Pentavac administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentavac administered first (Group B)
Trial: 15010066
Drug: Glufosfamide 5000
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glufosfamide 5000 mg/m² by 1-hour intravenous infusion every 3 weeks
Trial: 11758323
Drug: Infiltration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infiltration of 0.5% bupivacaine into the surgical wound before surgery combined with general anesthesia (Group L)
Trial: 30908574
Drug: Paracetamol responders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol responders
Trial: 30908574
Drug: Paracetamol nonresponders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol nonresponders
Trial: 29550881
Drug: Nabilone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabilone (0.5 mg/2 weeks followed by 1.0 mg/6 weeks)
Trial: 23302446
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens 0.625 mg/day for 4 weeks with antipsychotic treatment
Trial: 23302446
Drug: Placebo booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo booster with antipsychotics
Trial: 15806975
Drug: Shenfu injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenfu injection (SFI) plus stanozol and cyclosporin A
Trial: 7574195
Drug: Azithromycin prophylaxis
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin prophylaxis (250 mg/d) for cohort 1, administered as 500 mg on day 14 before challenge, followed by 250 mg/d from day 13 before challenge through day 7 after challenge.
Trial: 7574195
Drug: Azithromycin prophylaxis
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin prophylaxis (250 mg/d) for cohort 2, continued for 28 days after the challenge.
Trial: 7574195
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment) for both cohorts.
Trial: 2037705
Drug: Pinacidil (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinacidil (0.1 mg/kg)
Trial: 2037705
Drug: Pinacidil (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinacidil (0.1 mg/kg) with propranolol pretreatment
Trial: 7308332
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg bromhexine (4 mg in two patients)
Trial: 31124581
Drug: Dexamethasone (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (6 mg/m²/day)
Trial: 31124581
Drug: Prednisolone (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (60 mg/m²/day)
Trial: 29032379
Drug: Oral bicarbonate
RxNorm normalized name: sodium bicarbonate Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bicarbonate
Trial: 19725342
Drug: Sugammadex administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex administered at a dosage of 2 mg x kg(‐1)
Trial: 18027087
Drug: Post-operative radiation
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative radiation therapy (largely eliminated)
Trial: 18027087
Drug: Comparative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparative treatment regimens (randomized trials)
Trial: 15130189
Drug: Balanced and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced and complementary processing of text/adjunct information
Trial: 8091361
Drug: SR 25776
RxNorm normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR 25776 500 mg
Trial: 30460402
Drug: Tonsillectomy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tonsillectomy plus platelet-rich plasma (PRP) therapy (TPRP group)
Trial: 28870263
Drug: 3000 IU
RxNorm normalized name: Cholecalciferol 3000 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3000 IU vitamin D3 taken daily from randomization in pregnancy until trial discharge at 12 months postpartum